



13th November 2018

The Secretary
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

Clarification on the media report in the Indian Express

Dear Sir

This has reference to your email dated 12th November 2018 on the above subject.

We would like to inform you that we have recalled stocks of one batch of Lasix® from the market based on the directive issued by Kerala Drug Control department. Our control samples are in line with defined quality parameters and do not show any deviation. We are investigating the matter and have no further details to add at this stage.

We would like to also inform to you that this recall will not have any material impact on the financial statements and is not required to be reported to the Stock Exchanges as per the Policy adopted by the Company for determination of materiality for disclosure of events or information to the Stock Exchanges pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Regulations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For Sanofi India Limited

A handwritten signature in blue ink, appearing to read "Girish Tekchandani", is written over a light blue horizontal line.

Girish Tekchandani
Company Secretary